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cive case presentations are increasingly common at inter-
entional cardiology conferences. Taking advantage of sig-
ificant advances in communication technology, broadcasts
f procedures can be viewed as an extension of traditional
edical education targeted to large groups of practitioners.
owever, there are important ethical, commercial, and
atient safety issues associated with live cases that deserve
ttention. Use of investigational devices in live case dem-
nstrations is subject to review and approval by FDA’s
enter for Devices and Radiological Health (CDRH), and
he outcomes of patients participating in live cases are
onsidered in the overall clinical study results. This article
iscusses CDRH’s regulatory view of live case presentations
ith a focus on patient safety, clinical trial integrity, and
oncerns regarding improper medical device promotion.
ntroduction
he past 2 decades have witnessed a proliferation of live
ase demonstrations of interventional cardiology procedures
o treat coronary artery disease, structural heart disease,
eripheral vascular disease, and cardiac arrhythmias. These
resentations have often become integral parts of the
cientific sessions sponsored by cardiovascular professional
ocieties, large research foundations, and some individual
edical institutions.
Multiple ethical, promotional, and educational issues
urround the issue of live case presentations. Sade et al. (1),
n behalf of the American Association for Thoracic Surgery
thics Committee and the Society of Thoracic Surgeons
tandards and Ethics Committee strongly question the
alue of live case demonstrations. The authors highlight
atient safety risks and questionable medical ethics associ-
ted with live cases. Although they recognize that the
eaching of surgical techniques by direct observation of live
urgery in the surgeon’s home operating room is a time-
onored acceptable practice, they conclude that the educa-
ional benefits of broadcast live cases are “meager” compared
rom the Center for Devices and Radiological Health, Food and Drug Administra-
ion, Silver Spring, Maryland. This work represents the professional opinion of the
uthors and is not an official document, agency guidance or policy of the U.S.
overnment, the Department of Health and Human Services, or the Food and Drugt
dministration, nor should any official endorsement be inferred.
Manuscript received June 24, 2010, accepted June 28, 2010.o the potential harms faced by the participating patient.
hus, they recommend that national and international
ardiothoracic societies consider prohibiting live surgery
roadcasts at their annual meetings.
In contrast, a writing group composed on behalf of several
.S. and international cardiovascular professional societies,
n the current issue of the Catheterization and Cardiovascular
nterventions, the HeartRhythm Journal, and the Journal of
he American College of Cardiology, provide greater emphasis
n the merits of live case demonstrations and view them as
n evolutionary advance in physician teaching methods (2).
he authors attest to the inherent (but difficult to measure)
enefits of live cases for physician education, improved
uality of medical care, increased enrollment in clinical
rials, and fostering innovations in medical device develop-
ent. Importantly, the writing group recognize that there
re no objective measures of the educational value derived
rom the observation of live cases, and there is a paucity of
ata on the potential safety risks to patients who are subjects
f live cases. The authors rightfully acknowledge the cri-
ique of live case demonstrations presented by Sade et al.
1); in response, they offer a detailed program of measures
imed at mitigating patient risks and ethical concerns. Their
uggestions provide mechanisms to standardize the perfor-
ance of live cases to enhance patient safety and improve
heir educational value.
he FDA’s Role
he FDA’s broad public health mission is to provide
ssurance that drugs and devices are safe and effective for
heir intended uses. At the FDA, the Center for Devices
nd Radiological Health (CDRH) is responsible for estab-
ishing reasonable assurance of the safety and effectiveness of
edical devices prior to marketing in the United States.
ithin CDRH, the Office of Device Evaluation’s Division
f Cardiovascular Devices evaluates the safety and effective-
ess of devices used in interventional and electrophysiologic
ardiovascular procedures. The agency appreciates the range
f opinions offered by the authors representing thoracic
urgery and cardiology professional societies regarding the
erits of live case demonstrations (1,2). Although there are
lear individual patient welfare and public health implica-
ions associated with live cases, it is important to appreciate
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Live Case Presentations: Regulatory Considerations October 5, 2010:1283–5he FDA’s oversight role and the scope of its regulatory
eview of these procedures.
se of Investigational Devices
n Live Case Demonstrations
he FDA’s most important role in the regulation of live
ases occurs in the use of investigational non-FDA ap-
roved devices in patients enrolled in clinical trials in the
.S. It must be understood that the study of significant risk
napproved medical devices in any clinical study may only
ccur if a sponsor obtains approval of an Investigational
evice Exemption (IDE, 21 CFR 812) from the FDA. An
DE allows the use of investigational devices in clinical trials
f human subjects. Often, the objective of the clinical trial is
o collect data on device safety and effectiveness to support
premarket approval application (PMA) or a premarket
otification [510 (k)], which following FDA approval
PMA) or clearance [510 (k)], allows commercial marketing
nd use of the device. In other situations, an IDE is required
f a sponsor is seeking a new indication for an approved
evice or the clinical research study involves off-label use of
n approved device. An IDE provides protection to human
ubjects and ensures monitoring of the clinical study.
In the context of an unapproved device being used in an
DE study, FDA defines a live case presentation as:
“Treatment of a human subject under the auspices of an
pproved or conditionally approved IDE, conducted and
roadcast in real time, or recorded and broadcast at a later
ime, to an audience at a widely attended professional
cientific meeting.”
Since investigational devices are not available for use
utside of an IDE study (and might not ever become
vailable in the U.S. if the device does not ultimately receive
DA approval or clearance), the Agency’s view is that
he use of an unapproved device in live case demonstrations
hould be limited to providing increased awareness of the
DE study for potential investigators and practicing physi-
ians to augment the recruitment of study subjects.
The FDA approval of a live case presentation under the
uspices of an IDE study requires a formal request from the
ponsor and a detailed review by FDA staff; the application
hould be submitted at least 30 days prior to the live case
emonstration to allow adequate time for a comprehensive
valuation. The application form for a live case demonstra-
ion requires that the sponsor address many of the concerns
resented by the professional organizations (1,2). The
ponsor should identify whether the case will be presented
ive in real time or videotaped for later broadcast. The
DA’s primary focus regarding live cases is patient safety,
nd specific patient protection measures include:
• Institutional Review Board (IRB) approval. Approval
of the live case presentation by an independent IRB is
required.
• Risk analysis. A justification for a real time broadcast
should include a rationale describing why a videotaped lpresentation would not serve as an adequate substitute.
Procedural risks that may be increased by a live case
setting include infections, prolonged procedure and
anesthesia time, increased radiation exposure, in-
creased intravenous contrast use, distraction of the
operator, and patient privacy concerns. The applica-
tion should discuss measures to minimize these risks.
Although a case videotaped for later broadcast might
be associated with reduced risk compared to a live case,
the application process for FDA review and approval
for a planned videotape is the same as that for a case to
be shown live.
• Informed consent. A signed informed consent that
details potential additional risks posed by the live
presentation must be obtained prior to subject partic-
ipation. The consent document should outline confi-
dentiality issues (e.g., broadcast of the procedure and
possible recording for future viewing). A patient who
agrees to be a subject in a live case should be informed
that he or she should have no expectation of direct
benefit as a result of his or her participation.
ive case demonstrations of investigational devices may be
erformed only at approved investigational sites by investi-
ators who are currently participating in the study. Adher-
nce to the study protocol, data collection, and reporting of
dverse events apply equally to live cases as they do for all
ther patients enrolled in the IDE study. Any planned
eviations from the approved IDE study protocol should be
escribed and justified. Operators performing live cases
ust keep patient safety paramount and not compromise
linical decision-making or care for the sake of demonstrat-
ng a new device or technique. To reduce risks, we recom-
end that an on-site investigator (rather than the operator
ho is actively performing the procedure) primarily inter-
cts with the off-site moderator and panel. Unanticipated
dverse effects that occur during a live case presentation, or
dverse effects that occur at increased frequency, should be
eparately reported to the FDA in an IDE supplement
ithin 10 days.
Patients who participate in a live case count toward the
otal approved enrollment in the clinical trial, and proce-
ural and clinical outcomes in these patients have the
otential to affect the overall results of the study. Further, it
s understood that live case patients may be chosen for
pecific anatomic or clinical features of interest (introducing
election bias), and their participation may violate study
andomization or blinding. In the analysis of the study
esults, clinical outcomes of live case subjects should be
nalyzed separately and compared with the outcomes for the
est of the study population to assess whether these subjects
ere exposed to additional risks.
The FDA is sensitive to any overt or implied commercial
romotion of the investigational devices demonstrated in
ive cases. Sponsors should provide a rationale for why the
ive case presentation is not a form of product promotion or
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October 5, 2010:1283–5 Live Case Presentations: Regulatory Considerationsdvertising, and unapproved devices should be clearly iden-
ified as investigational during the broadcast and discussion
f the case. Extremely high risk procedures or interventions
n highly complex patients or anatomies are generally not
uitable for live case presentation involving devices under
DE investigation. In addition, invasive procedures in chil-
ren may be more technically challenging than in adults,
nd a live case presentation involving pediatric subjects must
resent no more than minimal additional risks. Live case
emonstrations in pediatric patients are associated with
pecial safety concerns (technically challenging anatomic
eatures and heightened attention to radiation exposure and
lood loss) and patient protection considerations (including
ssent by the child and parental permission); the sponsor
ust comprehensively address these pediatric-specific con-
erns in the request to the FDA for live case approval.
inally, use of an investigational device for compassionate
se or in a continued access study (that is initiated after IDE
nrollment has been completed) is not appropriate for live
ase presentations.
se of FDA-Approved Devices
n Live Case Demonstrations
hen not part of an IDE study, medical devices may be
sed either 1) in accordance with their FDA-approved
ndications for use (on-label use), or 2) off-label. Off-label
se refers to use of an approved medical product in diagnosis
r treatments other than those explicitly included in label-
ng. Although off-label use of a medical product should not
e interpreted as inappropriate or substandard clinical prac-
ice, in many cases, it does mean that data from well-
esigned clinical trials have not been developed that estab-
ish a reasonable assurance of safety and effectiveness for
DA approval for the specific condition. The on-label or
ff-label use of an approved medical device used in a live
ase demonstration is subject to IRB approval and informed
onsent. However, use of a device beyond its labeled
ndication should be publicly disclosed during the presen-
ation. Although the planned use of approved devices that
re not part of an IDE study in live cases is not subjected to
DA review and approval, the agency maintains an active
nterest in all live cases and can initiate disciplinary action if
he live case encourages or commercially promotes off-label
se of a medical device.
he FDA’s Reach
ith advances in communication technology, interven-
ional cardiology live case demonstrations are increasingly
K
clobal in nature and are transmitted from medical centers
orldwide. However, the FDA only has regulatory author-
ty over live case presentations of investigational medical
evices that are broadcast from sites within the US. It is our
ope that high standards of patient safety, privacy, and
thics are also applied to live case procedures performed
utside the U.S.
ummary
ive case presentations may be viewed as an extension of
raditional methods of medical education in an era of
nparalleled growth of communication and broadcast trans-
ission technology. However, the objective educational
enefits of live case presentations are difficult to measure,
nd potential patient safety and ethical concerns need to be
ecognized. As a public health regulatory agency, FDA has
mportant oversight of many aspects of live case demonstra-
ions with patient protection as its highest priority. FDA is
onsidering developing further guidance on live case pre-
entations during IDE clinical trials. Lastly, as there have
een few studies of adverse events or outcomes related to
ive cases (3,4), more research on procedural safety outcomes
uring live case presentations is needed to better define
atient risks, particularly at a time in which live case
resentations have become a cornerstone of many interven-
ional cardiology meetings.
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